Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

São Paulo - Delayed Quote BRL

AbbVie Inc. (ABBV34.SA)

Compare

72.27

+0.87

+(1.22%)

At close: February 21 at 6:05:00 PM GMT-3

2 High-Yield Dividend ETFs to Buy to Generate Passive Income

With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income.

Motley Fool 15 hours ago

^GSPC

CVX

ABBV
4 Seniors & Aging Demographics Stocks to Watch Right Now

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

Zacks 2 days ago

ABBV

SYK

AMGN
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings

AbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. Our analysis...

Simply Wall St. 2 days ago

ABBV
2 Magnificent Dividend Growth Stocks to Load Up On Right Now

Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles. This financial strength means they can often maintain and grow their dividends even during economic downturns, providing investors with steady income growth regardless of market conditions.

Motley Fool 3 days ago

ABBV

SPGI
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent

Bausch and Lomb chairman and CEO Brent Saunders

Yahoo Finance 4 days ago

BLCO

PFE

BHC
Top Analyst Reports for Home Depot, Booking & Eaton

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking Holdings Inc. (BKNG) and Eaton Corporation plc (ETN), as well as a micro-cap stock Value Line, Inc. (VALU).

Zacks 5 days ago

HD

ETN

ABBV
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best drug stocks to buy now. Is China the Next Big Thing in the Pharmaceutical Industry? Large American pharmaceutical companies are showing a […]

Insider Monkey 6 days ago

ABBV
AbbVie Full Year 2024 Earnings: EPS Misses Expectations

AbbVie ( NYSE:ABBV ) Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net income...

Simply Wall St. 7 days ago

ABBV
Is AbbVie Stock a Buy Now?

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share (EPS), with both metrics exceeding initial guidance. Comments by management projected optimism for continued growth momentum into the new year.

Motley Fool 8 days ago

ABBV
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs.

Zacks 9 days ago

ABBV

NVS

PFE
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013.

PR Newswire 9 days ago

ABBV
AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

PR Newswire 10 days ago

ABBV
AbbVie Inc. (ABBV): Among Lee Munder Capital Group’s Top Stock Picks

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Lee Munder Capital Group Investments, more commonly known as LMCG Investments, LLC, is an independent, employee-owned investment management […]

Insider Monkey 10 days ago

ABBV
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

BioPharma Dive 10 days ago

BIIB

ABBV

NMRA
Is AbbVie Inc. (NYSE:ABBV) Trading At A 47% Discount?

Key Insights The projected fair value for AbbVie is US$364 based on 2 Stage Free Cash Flow to Equity AbbVie's US$193...

Simply Wall St. 10 days ago

ABBV
AbbVie and Xilio to collaborate on antibody-based immunotherapies

Xilio will obtain upfront payments totalling $52m and including a $10m equity investment.

Pharmaceutical Technology 10 days ago

XLO

ABBV
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

On Wednesday, AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio’s proprietary technology. Xilio has developed a proprietary, clinically validated platform technology for tumor-activated biologics. The company is advancing a pipeline of clinical and preclinical immunotherapies, including masked multispecific m

Benzinga 11 days ago

XLO

ABBV
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new state-of-the-art training centers in the U.S. expanding access to high-quality, tailored training to licensed aesthetics providers. AMI's unique curriculum, designed to accelerate the science and art of aesthetics, paired with the company's outstanding portfolio of products, empowers providers and business owners to deliver desired patient outcomes and experiences.

PR Newswire 11 days ago

ABBV
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for peopl

GlobeNewswire 11 days ago

XLO

ABBV
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs. Analyst Paul Choi writes that AbbVie Inc partnered ABBV-RGX-314 faces growing competition, with its invasive delivery method making it less favorable than rival treatments. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of

Benzinga 12 days ago

RGNX

ABBV

Performance Overview

Return	ABBV34.SA	S&P 500
YTD	+6.55%	+2.24%
1-Year	+37.69%	+20.70%
3-Year	+72.59%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV34.SA)

2 High-Yield Dividend ETFs to Buy to Generate Passive Income

4 Seniors & Aging Demographics Stocks to Watch Right Now

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings

2 Magnificent Dividend Growth Stocks to Load Up On Right Now

Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent

Top Analyst Reports for Home Depot, Booking & Eaton

Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now

AbbVie Full Year 2024 Earnings: EPS Misses Expectations

Is AbbVie Stock a Buy Now?

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

AbbVie Declares Quarterly Dividend

AbbVie Inc. (ABBV): Among Lee Munder Capital Group’s Top Stock Picks

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Is AbbVie Inc. (NYSE:ABBV) Trading At A 47% Discount?

AbbVie and Xilio to collaborate on antibody-based immunotherapies

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Performance Overview